inb10qa_20100519.htm
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington
D.C. 20549
____________
FORM
10-Q/A
(Amendment No. 1)
x Quarterly Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
For the
quarterly period ended March 31, 2010
OR
o Transition Report Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
For the
transition period
from to
Commission File Number 001-31668
INTEGRATED BIOPHARMA,
INC.
(Exact
name of registrant, as specified in its charter)
|
Delaware
|
22-2407475 |
| (State
or other jurisdiction of incorporation or
organization) |
(I.R.S.
Employer Identification
No.) |
|
225
Long Ave., Hillside, New Jersey
|
07205
|
| (Address of principal executive
offices) |
(Zip
Code)
|
(888)
319-6962
(Registrant's telephone
number, including Area Code)
Not
Applicable
(Former
name, former address and former fiscal year, if changed since last
report)
Indicate
by check mark whether the Registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes x No
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
|
|
|
|
|
|
|
|
|
Large
accelerated filer
|
|
Accelerated
filer
|
|
Non-accelerated
filer
|
|
Smaller
reporting company x
|
Indicate by check whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).
Yes No x
Applicable
only to Corporate Issuers:
The
number of shares outstanding of each of the issuer’s class of common stock, as
of the latest practicable date:
|
Class
|
Outstanding at May 19,
2010
|
| Common Stock, $0.002
par value |
20,519,342
Shares |
Explanatory
Statement
This
Amendment No. 1 amends Integrated BioPharma, Inc.'s Quarterly Report on Form
10-Q for the quarter ended March 31, 2010 which was filed with the Securites and
Exchange Commission on May 19, 2010. The Company is filing this Amendment
No. 1 to correct a typographical error found in the Signature page to the
original filing. Accordingly, the Signature page has been amended to
reflect a correction of the typographical error.
This Amendment No. 1 does not include the entire Form 10-Q
except as described in this explanatory note. This Amendment No. 1 does
not amend any other information set forth in the original filing.
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the Company has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA,
INC.
| Date: May 19,
2010 |
|
By: |
/s/ E Gerald
Kay |
|
|
|
|
E. Gerald
Kay, |
|
|
|
|
President and
Chief Executive Officer |
| Date: May 19,
2010 |
|
By: |
/s/ Dina L.
Masi |
|
|
|
|
Dina L.
Masi, |
|
|
|
|
Chief
Financial Officer & Senior Vice
President |
34